Is Thymosin Alpha-1 Legal in Tennessee?
At a glance
- FDA approval / Not approved; no US application found [1]
- Other countries / Approved in Italy, India and Hong Kong [1]
- State-licensed pharmacy list / In none of the three categories [2]
- Outsourcing facilities / Category 3, nominated without adequate support [3]
- FDA advisory vote / 4 yes and 17 no on adding it to the pharmacy list [4]
- HHS peptide policy / Not one of the six peptides covered [5]
What is thymosin alpha-1's federal status?
Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide. It is not FDA-approved: a Drugs@FDA search found no US application [1]. FDA's December 2024 review notes four US orphan drug designations, but orphan designation is not approval [1].
It is approved in some other countries. FDA lists Italy, India and Hong Kong [1]. The European Medicines Agency has only an orphan designation for hepatocellular carcinoma, not a marketing approval [1]. Two older reviews by authors tied to the Zadaxin developer say it is approved in over 35 countries (2009) or more than 30 countries (2007) [6][7]. Zadaxin is the brand of the finished injection sold outside the US, at 1.6 mg per vial; it is not interchangeable with bulk powder [1].
Can it be compounded in the US?
On FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), thymosin alpha-1 appears in none of the three categories [2]. On FDA's list for outsourcing facilities (updated March 21, 2025), it is category 3, nominated without adequate support [3]. FDA's category 1 policy, under which FDA generally takes no action against compounders who meet conditions, does not apply to it [2][3].
FDA's page on bulk substances that may raise significant safety risks lists thymosin alpha-1 in its "nominated but withdrawn" table. It had been in category 2 and came off because the nominators withdrew it [8]. FDA's concerns remain posted: significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information inadequate for the agency to understand the extent of any safety issues [8].
FDA proposed that it not be added to the pharmacy bulk substances list [4]. On December 4, 2024, the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate form. Members who voted no cited no compelling evidence of clinical effectiveness and safety [4]. Thymosin alpha-1 is not among the six peptides in HHS's October 2026 draft enforcement-discretion policy, and no FDA or HHS action allowing its compounding has been identified [5].
What does the federal position mean for a Tennessee patient?
Federal law addresses pharmacy compounding, while state boards of pharmacy have primary responsibility for day-to-day oversight of state-licensed pharmacies [9]. The FDA list entries above settle only the federal side. They do not show that thymosin alpha-1 may be supplied in Tennessee, and they say nothing about Tennessee law specifically.
Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed [9].
No US-approved dose exists. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first influenza vaccination, repeated from week 8 to week 12 at the second [1].
Frequently asked questions
Is thymosin alpha-1 legal in Tennessee?
Is thymosin alpha-1 FDA-approved?
Can a compounding pharmacy make thymosin alpha-1?
What safety concerns does FDA list for thymosin alpha-1?
Is thymosin alpha-1 on the WADA prohibited list?
References
Show all 11 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Compounding and the FDA: Questions and Answers | FDA.
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
- World Anti-Doping Agency.